Vanda Pharmaceuticals (VNDA) Operating Income (2016 - 2025)
Historic Operating Income for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q3 2025 value amounting to -$31.3 million.
- Vanda Pharmaceuticals' Operating Income fell 18440.0% to -$31.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.1 million, marking a year-over-year decrease of 22313.28%. This contributed to the annual value of -$40.7 million for FY2024, which is 19142.78% down from last year.
- Per Vanda Pharmaceuticals' latest filing, its Operating Income stood at -$31.3 million for Q3 2025, which was down 18440.0% from -$38.5 million recorded in Q2 2025.
- Vanda Pharmaceuticals' 5-year Operating Income high stood at $12.4 million for Q2 2021, and its period low was -$41.0 million during Q1 2025.
- Over the past 5 years, Vanda Pharmaceuticals' median Operating Income value was -$6.0 million (recorded in 2023), while the average stood at -$6.2 million.
- In the last 5 years, Vanda Pharmaceuticals' Operating Income skyrocketed by 837280.0% in 2021 and then plummeted by 56082.83% in 2024.
- Vanda Pharmaceuticals' Operating Income (Quarter) stood at $8.6 million in 2021, then dropped by 23.24% to $6.6 million in 2022, then crashed by 207.01% to -$7.1 million in 2023, then crashed by 44.9% to -$10.3 million in 2024, then plummeted by 204.35% to -$31.3 million in 2025.
- Its Operating Income stands at -$31.3 million for Q3 2025, versus -$38.5 million for Q2 2025 and -$41.0 million for Q1 2025.